Randomised phase II trial of mFOLFOX6 plus bevacizumab versus mFOLFOX6 plus cetuximab as first-line treatment for colorectal liver metastasis (ATOM trial)

BACKGROUND: Chemotherapy with biologics followed by liver surgery improves the resection rate and survival of patients with colorectal liver metastasis (CRLM). However, no prospective study has compared the outcomes of chemotherapy with bevacizumab (BEV) versus cetuximab (CET). METHODS: The ATOM stu...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Br J Cancer
Autores principales: Oki, Eiji, Emi, Yasunori, Yamanaka, Takeharu, Uetake, Hiroyuki, Muro, Kei, Takahashi, Takao, Nagasaka, Takeshi, Hatano, Etsuro, Ojima, Hitoshi, Manaka, Dai, Kusumoto, Tetsuya, Katayose, Yu, Fujiwara, Toshiyoshi, Yoshida, Kazuhiro, Unno, Michiaki, Hyodo, Ichinosuke, Tomita, Naohiro, Sugihara, Kenichi, Maehara, Yoshihiko
Formato: Artigo
Lenguaje:Inglês
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC6738101/
https://ncbi.nlm.nih.gov/pubmed/31285591
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0518-2
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares